MXPA03000406A - Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos. - Google Patents

Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.

Info

Publication number
MXPA03000406A
MXPA03000406A MXPA03000406A MXPA03000406A MXPA03000406A MX PA03000406 A MXPA03000406 A MX PA03000406A MX PA03000406 A MXPA03000406 A MX PA03000406A MX PA03000406 A MXPA03000406 A MX PA03000406A MX PA03000406 A MXPA03000406 A MX PA03000406A
Authority
MX
Mexico
Prior art keywords
compound
activity
bone
1agr
dihydroxyvitamin
Prior art date
Application number
MXPA03000406A
Other languages
English (en)
Inventor
Hector F Deluca
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of MXPA03000406A publication Critical patent/MXPA03000406A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invencion proporciona una clase novedosa de compuestos relacionados con vitamina D, es decir los derivados 2-alquiliden-19-nor- vitamina D, así como un método general para su síntesis química. Los compuestos tienen la formula (I) en donde Y1 e Y2 que pueden ser iguales o diferentes, cada uno se elige del grupo que consiste de hidrogeno y un grupo hidroxi protector, R6 y R8, que pueden ser iguales o diferentes, cada uno se eligen de hidrogeno, alquilo e hidroxi alquilo y fluoroalquilo, o cuando se toman juntos representan el grupo -(CH2)x en donde x es un entero de 2 a 5 y en donde el grupo R representa cualquiera de las cadenas laterales típicas conocidas para compuestos del tipo vitamina D. Estos compuestos 2-substituidos se caracterizan por alta actividad de transporte de calcio intestinal y actividad de movilizacion de calcio en huesos relativamente alta, resultando en agentes terapéuticos para el tratamiento de enfermedades en donde se desea formacion de huesos, particularmente osteoporosis de bajo recambio de huesos. Estos compuestos también exhiben actividad pronunciada para frenar la proliferacion de células no diferenciadas e inducir su diferenciacion al monolito, de esta manera evidenciando uso como agentes anti-cáncer y para tratamiento de enfermedades tales como psoriasis.
MXPA03000406A 2000-07-14 2001-07-10 Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos. MXPA03000406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61616400A 2000-07-14 2000-07-14
PCT/US2001/021706 WO2002005823A2 (en) 2000-07-14 2001-07-10 USE OF 2-METHYLENE-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH

Publications (1)

Publication Number Publication Date
MXPA03000406A true MXPA03000406A (es) 2003-06-06

Family

ID=24468290

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000406A MXPA03000406A (es) 2000-07-14 2001-07-10 Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.

Country Status (13)

Country Link
US (3) US7115594B2 (es)
EP (1) EP1301189A2 (es)
JP (1) JP2004505022A (es)
KR (1) KR100572957B1 (es)
CN (1) CN1217664C (es)
AU (2) AU2001278888B2 (es)
BR (1) BR0112454A (es)
CA (1) CA2416194C (es)
HK (1) HK1060304A1 (es)
IL (2) IL153907A0 (es)
MX (1) MXPA03000406A (es)
NZ (1) NZ537036A (es)
WO (1) WO2002005823A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
WO2004076468A1 (ja) 2003-02-25 2004-09-10 Kobe Tennenbutsu Kagaku Kabushiki Kaisha ビタミンｄ誘導体を合成するための新規な中間体
WO2005027924A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
WO2005027920A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency
WO2005027930A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylene-19-nor-vitamin d derivatives for the treatment of osteosarcoma
WO2005027919A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
US7214670B2 (en) * 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
AU2005303773A1 (en) 2004-11-12 2006-05-18 Bioxell Spa Combined use of vitamin D derivatives and anti-proliferative agents for treating bladder cancer
DE602005021245D1 (de) * 2004-11-22 2010-06-24 Wisconsin Alumni Res Found 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
WO2006061683A1 (en) * 2004-12-09 2006-06-15 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta
EP2021320A2 (en) 2006-04-06 2009-02-11 Wisconsin Alumni Research Foundation 2-substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof
US8193169B2 (en) 2006-04-06 2012-06-05 Wisconsin Alumni Research Foundation (20R)-2α-methyl-19,26,2-trinor-vitamin D analogs
US20110034426A1 (en) * 2009-08-03 2011-02-10 Wisconsin Alumni Research Foundation Method of Preventing Renal Disease and Treating Symptoms Thereof
AU2011232633B2 (en) * 2010-03-23 2014-05-29 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22- dimethyl-1alpha,25-hydroxyvitamin D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
EP2556054B1 (en) * 2010-03-23 2017-09-27 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
MX2015000076A (es) 2012-06-29 2015-04-10 Wisconsin Alumni Reasearch Foundation Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
EP0619306B1 (en) * 1993-04-05 1996-09-11 Wisconsin Alumni Research Foundation 19-Nor-vitamin D3 compounds with substituent at 2-position
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength

Also Published As

Publication number Publication date
KR100572957B1 (ko) 2006-04-24
US20060135492A1 (en) 2006-06-22
NZ537036A (en) 2006-07-28
CA2416194C (en) 2009-10-06
AU7888801A (en) 2002-01-30
WO2002005823A2 (en) 2002-01-24
KR20030016403A (ko) 2003-02-26
AU2001278888B2 (en) 2005-04-07
HK1060304A1 (en) 2004-08-06
US20060135493A1 (en) 2006-06-22
CA2416194A1 (en) 2002-01-24
IL153907A (en) 2009-08-03
CN1455672A (zh) 2003-11-12
JP2004505022A (ja) 2004-02-19
US20040068129A1 (en) 2004-04-08
US7115594B2 (en) 2006-10-03
WO2002005823A3 (en) 2002-05-23
EP1301189A2 (en) 2003-04-16
BR0112454A (pt) 2003-07-29
CN1217664C (zh) 2005-09-07
IL153907A0 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
MXPA03000405A (es) Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos.
MXPA03000406A (es) Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
HK1086817A1 (en) 2- propylidene-19-nor-vitamin d compounds
HK1080728A1 (en) (20s)-1alpha-hydroxy-2alpha-methyl, and 2beta-methyl-19-nor-vitamin d3 and their uses
ATE534623T1 (de) 2-alkyliden-18,19-dinor-vitamin-d-verbindungen
EP1656157A4 (en) 2-METHYLENE-19-NOR-VITAMIN D2 COMPOUNDS
SG148037A1 (en) Fgf variants and methods for use thereof
BR0308355A (pt) Composto ou um sal farmaceuticamente aceitável ou um seu enanciÈmero, métodos para modular uma função mediada pelo receptor de androgênio em um mamìfero em necessidade de tal modulação, para ativar a função do receptor de androgênio em um mamìfero em necessidade de tal ativação, para tratar uma condição em um mamìfero, e para tratar osteoporose em um mamìfero em sua necessidade, composição farmacêutica, métodos para aumentar a densidade mineral óssea em um mamìfero em necessidade disto, para reduzir o risco de fraturas vertebrais ou não vertebrais em um mamìfero em necessidade disto, e para produzir um marcador de modificação óssea em um mamìfero em necessidade disto, processo para produzir uma composição farmacêutica, e, método para tratar ou prevenir uma condição artrìtica em um mamìfero em necessidade disto
HK1079996A1 (en) Use of carbon-2-modified-19-nor-vitamin d analogs in the manufacture of a medicament for inducing the formation of new bone
AR010873A1 (es) Compuestos antagonistas del receptor de vitronectina, intermediarios, metodos de su preparacion, composiciones farmaceuticas, uso de dichoscompuestos para la fabricacion de medicamentos.
Li et al. What we have achieved in the design of 3D printed metal implants for application in orthopedics? Personal experience and review
Muzaffar et al. Functional results after osteosynthesis of distal humeral fractures with pre-contoured LCP system
CN201350104Y (zh) 髌骨改良锁定钢板
ATE350043T1 (de) 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
AU2002235991A1 (en) Use of the g-csf as adjuvant treatment in connective tissue recontruction
Iyer The Adult Hip and Its Disorders
ZA202100897B (en) Composition for improved bone fracture healing
Rekha Study of intercondylar fractures of the distal humerus treated with 90-90 plating
UA36327A (uk) Пристрій для остеосинтезу багатоосколкових переломів передньої частини п'яткової кістки з фрагментацією задньої суглобової фасетки
UA28851A (uk) Спосіб оперативного лікування переломів дистального метаепіфізу великогомілкової кістки

Legal Events

Date Code Title Description
FG Grant or registration